Lifecore Biomedical, Inc. (NASDAQ:LFCR) Shares Sold by 272 Capital LP

272 Capital LP lessened its stake in Lifecore Biomedical, Inc. (NASDAQ:LFCR) by 83.9% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 23,478 shares of the company’s stock after selling 121,981 shares during the quarter. 272 Capital LP owned about 0.08% of Lifecore Biomedical worth $120,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Allegheny Financial Group LTD purchased a new stake in Lifecore Biomedical in the 2nd quarter valued at $52,000. Renaissance Technologies LLC acquired a new position in shares of Lifecore Biomedical during the 2nd quarter valued at about $56,000. SG Americas Securities LLC purchased a new stake in shares of Lifecore Biomedical in the first quarter valued at about $57,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Lifecore Biomedical during the first quarter worth about $58,000. Finally, Boston Partners purchased a new position in Lifecore Biomedical during the first quarter worth about $104,000. Institutional investors and hedge funds own 83.36% of the company’s stock.

Lifecore Biomedical Stock Down 2.2 %

Shares of NASDAQ:LFCR opened at $4.89 on Tuesday. The company has a market capitalization of $148.27 million, a price-to-earnings ratio of -1.46 and a beta of 0.95. Lifecore Biomedical, Inc. has a 12-month low of $3.68 and a 12-month high of $8.90. The business has a 50-day moving average price of $5.30 and a 200 day moving average price of $5.67. The company has a current ratio of 2.08, a quick ratio of 1.06 and a debt-to-equity ratio of 12.90.

Lifecore Biomedical (NASDAQ:LFCR) last announced its quarterly earnings results on Monday, August 26th. The company reported ($0.15) earnings per share for the quarter. The company had revenue of $37.89 million for the quarter. Lifecore Biomedical had a net margin of 9.37% and a negative return on equity of 515.12%. Sell-side analysts expect that Lifecore Biomedical, Inc. will post -0.89 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. Craig Hallum assumed coverage on shares of Lifecore Biomedical in a research note on Thursday, September 5th. They issued a “buy” rating and a $8.00 price target for the company. Barrington Research lowered Lifecore Biomedical from an “outperform” rating to a “market perform” rating in a research report on Wednesday, August 28th.

Lifecore Biomedical Profile

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.